Conclusion

ME/CFS research has identified mechanisms and treatments with implications extending far beyond ME/CFS diagnostic boundaries. The most impactful translational findings are:

• Plasma cell autoimmunity: Explains why rituximab fails but daratumumab succeeds
• \(\beta\) 2-adrenergic receptor dysfunction: Links MCAS, POTS, and vascular pathology
• Vascular-immune-energy triad: Coordinated dysfunction requiring multi-target treatment
• NAD⁺ depletion: Universal mechanism affecting multiple organ systems
• Pacing protocols: Applicable to any condition with exercise intolerance These findings demonstrate that ME/CFS is not an isolated condition but shares fundamental pathophysiology with multiple other diseases. Cross-pollination of research between ME/CFS and related conditions will accelerate progress for all patient populations. Critical caveat: All translational recommendations require validation through condition-specific research. These represent research opportunities and clinical hypotheses, not established treatment guidelines for non-ME/CFS conditions. Clinicians and patients should approach these findings with appropriate scientific skepticism while recognizing their potential to advance understanding and treatment across the spectrum of post-viral, autoimmune, mitochondrial, and dysautonomic disorders.